As other Biologics indicated to treat plaque psoriasis or psoriatic arthritis have distinct interleukin receptors as targets (i.e., IL-17R), spesolimab brings a new mechanism of action by binding to IL-36R (interleukin-36 receptor), thereby inhibiting IL-36 from binding to IL-36R [20], since GPP seems to have a singular mechanism in its pathogenesis involving the IL-36R [60]. This evidence concerns the gene IL1RL2 and psoriatic arthritis.